Andrew Stanleick has a new gig.
The former longtime Coty executive, who was most recently chief executive officer of publicly listed BeautyHealth, has been named Kenvue Inc.’s president of skin health and beauty in North America, Europe, Middle East and Africa.
His remit will include brands like Neutrogena, Aveeno and OGX, in those regions.
“We are very pleased to have Andrew join Kenvue in this critical role,” said Charmaine England, chief growth officer at Kenvue. “With over two decades of experience in leading the profitable growth and omnichannel transformation of global multibrand portfolios in skin health, beauty and fashion, Andrew brings a proven track-record of success and deep industry knowledge to strengthen the growth trajectory of our skin health and beauty segment in key markets.”
Stanleick added: “As a global leader in consumer health, Kenvue’s iconic skin health and beauty brands have been trusted by consumers and recommended by health care professionals for generations. I look forward to helping these brands reach more consumers in new ways in 2025 and beyond.”
Prior to joining Kenvue, Stanleick served as the president and CEO of BeautyHealth, owner of the Hydrafacial device. Before that, he was executive vice president of Coty Americas, overseeing their portfolio of luxury and consumer brands across the region. He also served as the global CEO for the joint venture with Kylie Jenner Beauty and oversaw the Kim Kardashian business.
Earlier in his career, Stanleick spent several years as president and CEO of Coach, Europe and South Asia and Pacific.
Kenvue was spun out of Johnson & Johnson in May 2023 as its own public entity, focused on the consumer side of the business. In its fiscal second quarter ended June 30, net sales totaled $4 billion, down 0.3 percent from the year prior, but above Wall Street expectations. But within that, its skin health business saw sales drop 4 percent to $1.16 billion.
Most recently, activist investor group Starboard Value took a large stake in Kenvue, and zeroed in on how in can improve its skin care offering, which is understood to be worth around $5 billion.
“Kenvue has a strong portfolio of leading consumer brands, but its potential has not been fully realized. There’s a clear opportunity to improve revenue growth and margins in key segments like skin health,” Starboard CEO Jeff Smith said in a presentation at 13D Monitor’s Active-Passive Investor Summit last month.
